Biosimilars: Implications for health-system pharmacists

American Journal of Health-System Pharmacy

Volumn 70, Issue 22, 2013, Pages 2004-2017

  Lucio, Steven D ^a   Stevenson, James G ^b,c   Hoffman, James M ^d,e,f  

^a Solutions and Pharmacy Program Development Novation   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d and Medication Outcomes   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; GENERIC DRUG;

ARTICLE; COST CONTROL; DRUG COST; DRUG SURVEILLANCE PROGRAM; EUROPE; GENE SEQUENCE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; KNOWLEDGE; MOLECULE; PATIENT SAFETY; PHARMACIST; PRODUCT DEVELOPMENT; PUBLICATION; SAFETY; UNITED STATES; DRUG APPROVAL; DRUG DESIGN; FOOD AND DRUG ADMINISTRATION; HOSPITAL PHARMACY; ORGANIZATION AND MANAGEMENT; PATENT; PROFESSIONAL STANDARD; STANDARD;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PHARMACISTS; PHARMACOVIGILANCE; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84905134522     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130119     Document Type: Article

References (72)

1. Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures in U.S. nonfederal hospitals and clinics - 2013. Am J Health-Syst Pharm. 2013; 70:525-39.
2. Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures - 2012. Am J Health-Syst Pharm. 2012; 69:405-21.
3. Generic drug savings in the U.S. (fourth annual edition: 2012). Washington, DC: Generic Pharmaceutical Association; 2012:3.
4. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011; 3:209-17.
5. Fein AJ. 7 reasons why specialty drug dispensing will boom. www.specialtypharmacytimes.com/publ ications/specialty-pharmacy-times/2012/june-2012/7-Reasons-Why-Specialty-Drug-Dispensing-Will-Boom (accessed 2013Feb 1).
6. Sensabaugh SM. Requirements for biosimilars and interchangeable biological drugs in the United States - in plain language. Drug Inf J. 2011; 45:155-62.
7. Li E, Hoffman JM. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know. J Natl Compr Canc Netw. 2013; 11:368-72.
8. Title VII: Improving access to innovative medical therapies. Subtitle A: Biologic Price Competition and Innovation provisions of the Patient Protection and Affordable Care Act (PPACA). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf (accessed 2013 Feb 16).
9. Weise M, Bielsky MC, de Smet K et al. Biosimilars - why terminology matters. Nat Biotechnol. 2011; 29:690-3.
10. Zelenetz AD, Ahmed I, Braud EL et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011; 9(suppl 4):S1-22.
11. Zyvox (linezolid) package insert. New York, NY: Pfizer Inc.; 2012 Mar.
12. Zofran (ondansetron) package insert. Research Triangle Park, NC: GlaxoSmith-Kline; 2012 Jun.
13. Cubicin (daptomycin) package insert. Lexington, MA: Cubist Pharmaceuticals, Inc.; 2010 Nov.
14. Lovenox (enoxaparin) package insert. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2011 Apr.
15. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008; 18:335-42.
16. Neupogen (filgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2012 May.
17. Neulasta (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2012 May.
18. Rituxan (rituximab) package insert. South San Francisco, CA: Genentech, Inc; 2012 Jul.
19. Remicade (infliximab) package insert. Horsham, PA: Janssen Biotech, Inc.; 2011 Oct.
20. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2006; 21(suppl 5):v4-8.
21. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008; 19:412-9.
22. Carver KH, Elikan J, Lietzan E. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009. Food Drug Law J. 2010; 65:670-818.
23. Falk JI, Davidson RA. Coping with the regulatory realities of follow-on biologics and the nuances of US and European regulations. Drug Inf J. 2010; 44:137-45.
24. United States Adopted Names Council. www.ama-assn.org/ama/pub/physicianresources/medical-science/united-statesadopted-names-council.page (accessed 2013 Feb 5).
25. Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, draft guidance (February 2012). www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM273001.pdf (accessed 2013 Feb 5).
26. Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, draft guidance, February 2012. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 2013 Feb 5).
27. American Society of Health-System Pharmacists. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health-Syst Pharm. 2008; 65:1272-83.
28. IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/ Documents/Biosimilars-White-Paper.pdf (accessed 2013 Feb 1).
29. European Medicines Agency. European public assessment reports. www.ema.europa.eu (accessed 2013 Feb 10).
30. Hospira, Inc. Hospira's Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in Europe [news release]. http://phx.corporate-ir.net/phoenix.zhtml?c=175550&p= irolnewsArticle&ID=1853480&highlight = (accessed 2013 Sep 13).
31. Barnes K, Kim K. J & J's Remicade sixmonth patent extension to stave off Celltrion biosimilar threat in major EU markets (2013 Apr 29). www.ft.com/intl/cms/s/2/3b389dae-b100-11e2-80f9-00144feabdc0.html#axzz2VY6cVimM (accessed 2013 May 1).
32. Weise M, Bielsky MC, de Smet K et al. Biosimilars: what clinicians should know. Blood. 2012; 120:5111-7.
33. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012; 91:405-17.
34. Minsk A, Nguyen L, Cohen DR. The 505(b)(2) new drug application process: the essential primer, June 2010. www.fdli.org (accessed 2013 Jan 15).
35. Sutter S. Biosimilar interchangeability: stakeholders want more FDA guidance, fewer hurdles. FDC Rep: The Pink Sheet. 2012; 74(Apr 30):27-9.
36. Food and Drug Administration. Guidance for Industry. Quality considerations in demonstrating biosimilarity to a reference protein product, draft guidance, February 2012. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM291134.pdf (accessed 2013 Feb 5).
37. Palmer E. Abbott stands alone in challenge to biosimilars law. June 22, 2012. www.fiercepharma.org (accessed 2013 Jan 1).
38. International Conference on Harmonisation. Vision statement. www.ich.org/about/vision.html (accessed 2013 Feb 24).
39. International Conference on Harmonisation. ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process. www.fda.gov/OHRMS/DOCKETS/98fr/2004d-0118-gdl0001.pdf (accessed 2012 Oct 1).
40. Schiestl M, Stangler T, Torella C et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011; 29:310-2.
41. Schellekens H. Biosimilar therapeutics - what do we need to consider? NDT Plus. 2009; 2(suppl 1):i27-36.
42. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic" - mystery completely revealed? Perit Dial Int. 2007; 27:S303-7.
43. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004; 351:1403-8.
44. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008; 48:1754-62.
45. Kuhlmann M, Marre M. Lessons learned from biosimilars epoetins and insulins. Br J Diabetes Vasc Dis. 2010; 10:90-7.
46. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005; 25:954-62.
47. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011; 80:88-92.
48. Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf. 2012; 11:819-40.
49. Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colonystimulating factors. Expert Opin Drug Saf. 2013; 12:235-46.
50. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012; 12:1473-85.
51. Brinks V, Hawe A, Basmeleh AH et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011; 28:386-93.
52. Herper M. Amgen's planned assault on on AbbVie, Roche, and Lilly. www.forbes.com/sites/matthewherper/2013/02/07/amgensplanned-assault-on-abbvie-roche-andlilly/(accessed 2013 Feb 8).
53. GaBI Online. US $67 billion worth of biosimilar patents expiring before 2020. www.gabionline.net/Biosimilars/General/US-67-bi llion-worth-ofbiosimilar-patents-expiring-before-2020 (accessed 2013 Feb 1).
54. Covic A, Cannata-Andia J, Cancarini G et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephol Dial Transplant. 2008; 23:3731-7.
55. Strober BE, Armour K, Romiti R et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012; 66:317-22.
56. Kramer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis. 2010; 10:163-71.
57. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol. 2011; 86:277-88.
58. Lee JF, Litten JF, Grampp G. Comparability and biosimilarity: considerations for the health care provider. Curr Med Res Opin. 2012; 28:1053-8.
59. Industry Standard Research. Alliance for Safe Biologic Medicines - prescriber survey. http://safebiologics.org/resources/wp-content/uploads/2012/09/ASBMSurvey-1.pdf (accessed 2012 Oct 2).
60. ASHP Advantage. Preparing for biosimilars: scientific, regulatory, and practice management issues for pharmacists. www.ashpadvantage.com/biosimcentral/(accessed 2013 Jun 1).
61. Pollack A. Biotech firms, billions at risk, lobby states to limit generics. www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-ofbiotech- drugs.html?-r=0 (accessed 2013 Jan 28).
62. Generic Pharmaceutical Association. Illinois is latest state to avoid burdensome provisions in biosimilars bill [news release]. www.gphaonline.org/gpha-media/press/illinois-is-latest-state-to-avoidburdensome-provisions-in-biosimilarsbills (accessed 2013 Sep 20).
63. EMD Serono specialty digest: managed care strategies for specialty pharmaceuticals, 8th ed. Rockland, MA: EMD Serono; 2012:31.
64. Principles of a sound formulary system [consensus statement]. In: Hawkins B, ed. Best practices for hospital & health-system pharmacy: positions and guidance documents of ASHP. Bethesda, MD: American Society of Health-System Pharmacists; 2006:110-3.
65. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist. 2004; 9:451-8.
66. Brophy DR, Ripley EB, Kockler DR et al. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis. Ann Pharmacother. 2005; 39:1808-11.
67. Rubino M, Hoffman JM, Koesterer LJ et al. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 651:1368-84.
68. American Society of Health-System Pharmacists. Policy statement 1218: approval of biosimilar medications. www.ashp.org/DocLibrary/BestPractices/policypositions2013.aspx (accessed 2013 Mar 1).
69. Casadevall N, Edwards IR, Felix T et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther. 2013; 13:1039-47.
70. Food and Drug Administration. FDA approves new treatment for severe neutropenia in certain cancer patients. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm (accessed 2012 Oct 1).
71. Teva Pharmaceuticals. Teva announces FDA grants approval for tbo-filgrastim for the treatment of chemotherapy-induced neutropenia. www.tevapharm.com/Media/News/Pages/2012/1730014.aspx (accessed 2012 Oct 1).
72. Granix (tbo-filgrastim) package insert. North Wales, PA: Teva Pharmaceuticals USA; 2013 May.